secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001193125-26-047544
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics reports $5.8M cash, $16.4M debt; engages LifeSci Capital for reverse merger
--------------------------------------------------------------------------------

- As of Dec 31, 2025, cash and short-term investments total $17.7M; EIB Loan outstanding $16.4M.
- Lead drug candidate eDSP failed NEAT trial; no other products; no meaningful operations.
- Engaged LifeSci Capital on Feb 9, 2026 to evaluate strategic alternatives including reverse merger.
- Common stock closing bid price below $1.00 since Jan 29, 2026; Nasdaq delisting risk.
- May need bankruptcy protection if reverse merger fails; Bank has not invoked MAC clause yet.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526047544/0001193125-26-047544-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526047544/d89820d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-047544

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer